Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of XTMAB-16 in pulmonary sarcoidosis
2023-507590-18-00Phase 2Completed
- Sponsor
- Xentria
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of xtmab-16 in pulmonary sarcoidosis and sarcoidosis, sponsored by Xentria. Primary endpoint: Rate of adverse events. Started Jun 2025; status: completed.
02
Drugs
xtmab-16
03
Conditions
pulmonary sarcoidosissarcoidosis
Beyond the preview
Go deeper on 2023-507590-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507590-18-00.